Researchers report why Alzheimer's drugs work in the lab but not in patients

Researchers report why Alzheimer's drugs work in the lab but not in patients:

Dementia Big
A tremendous amount of amyloid-β peptide (Aβ) (a peptide of ~40 amino acids) accumulates in the brains of Alzheimer’s disease patients. γ-Secretase inhibitors were designed to inhibit the enzymatic activity that produces Aβ. By reducing Aβ production, γ-secretase inhibitors were able to treat Alzheimer’s disease (Aβ hypothesis). In fact, nearly 50 clinical trials have been conducted using potential γ-secretase inhibitors for Alzheimer’s disease or several types of cancer. However, all of these trials failed, except for two studies which are currently ongoing.

http://ift.tt/2zH7UVi